よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (53 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
157.
Schäfer W, Reinders T, Schink T. Second dose of measles-mumps-rubella-varicella vaccine
(MMRV) and the risk of febrile convulsions. Vaccine 2022; 40(14): 2168–72.
158.
France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-
mumps-rubella immunization in children. Pediatrics 2008; 121(3): e687–92.
159.
Andrews N, Stowe J, Miller E, et al. A collaborative approach to investigating the risk of
thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine
2012; 30(19): 3042–6.
160.
Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific
colitis, and pervasive developmental disorder in children. Lancet 1998; 351(9103): 637–41.
161.
Breggin PR. Moving past the vaccine/autism controversy - to examine potential vaccine
neurological harms. Int J Risk Saf Med 2021; 32(1): 25–39.
162.
Qian M, Chou SY, Lai EK. Confirmatory bias in health decisions: Evidence from the MMR-
autism controversy. J Health Econ 2020; 70: 102284.
163.
DeStefano F, Shimabukuro TT. The MMR Vaccine and Autism. Annu Rev Virol 2019; 6(1):
585–600.
164.
DeStefano F, Chen RT. Autism and measles, mumps, and rubella vaccine: No epidemiological
evidence for a causal association. J Pediatr 2000; 136(1): 125–6.
165.
Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing
vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine
Safety Datalink project. Arch Pediatr Adolesc Med 2001; 155(3): 354–9.
166.
Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella
vaccines. Bull World Health Organ 2000; 78(2): 199–204.
53
Schäfer W, Reinders T, Schink T. Second dose of measles-mumps-rubella-varicella vaccine
(MMRV) and the risk of febrile convulsions. Vaccine 2022; 40(14): 2168–72.
158.
France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-
mumps-rubella immunization in children. Pediatrics 2008; 121(3): e687–92.
159.
Andrews N, Stowe J, Miller E, et al. A collaborative approach to investigating the risk of
thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine
2012; 30(19): 3042–6.
160.
Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific
colitis, and pervasive developmental disorder in children. Lancet 1998; 351(9103): 637–41.
161.
Breggin PR. Moving past the vaccine/autism controversy - to examine potential vaccine
neurological harms. Int J Risk Saf Med 2021; 32(1): 25–39.
162.
Qian M, Chou SY, Lai EK. Confirmatory bias in health decisions: Evidence from the MMR-
autism controversy. J Health Econ 2020; 70: 102284.
163.
DeStefano F, Shimabukuro TT. The MMR Vaccine and Autism. Annu Rev Virol 2019; 6(1):
585–600.
164.
DeStefano F, Chen RT. Autism and measles, mumps, and rubella vaccine: No epidemiological
evidence for a causal association. J Pediatr 2000; 136(1): 125–6.
165.
Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing
vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine
Safety Datalink project. Arch Pediatr Adolesc Med 2001; 155(3): 354–9.
166.
Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella
vaccines. Bull World Health Organ 2000; 78(2): 199–204.
53